{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T10:36:32Z","timestamp":1717065392961},"reference-count":17,"publisher":"Japanese Society of Internal Medicine","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2015]]},"DOI":"10.2169\/internalmedicine.54.4996","type":"journal-article","created":{"date-parts":[[2015,12,14]],"date-time":"2015-12-14T17:02:48Z","timestamp":1450112568000},"page":"3185-3188","source":"Crossref","is-referenced-by-count":8,"title":["Alternate-day Treatment with Crizotinib for Drug-induced Esophagitis and Liver Damage in a Patient with EML4-ALK Fusion Gene-positive Lung Adenocarcinoma"],"prefix":"10.2169","volume":"54","author":[{"given":"Yoko","family":"Tsukita","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Miyagi Cancer Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuro","family":"Fukuhara","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Miyagi Cancer Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maki","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Miyagi Cancer Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mami","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Miyagi Cancer Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Miyagi Cancer Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kana","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Miyagi Cancer Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Noguchi","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medicine, Miyagi Cancer Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuko","family":"Kurata","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Okayama University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Suno","sequence":"additional","affiliation":[{"name":"Center for the Development of Medical and Health Care Education, Okayama University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Maemondo","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Miyagi Cancer Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693-1703, 2010.","DOI":"10.1056\/NEJMoa1006448"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Ou SH, Kwak EL, Siwak-Tapp C, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 6: 942-946, 2011.","DOI":"10.1097\/JTO.0b013e31821528d3"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Bergethon K, Shaw AT, Ou SH, et al. <i>ROS1<\/i> rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30: 863-870, 2012.","DOI":"10.1200\/JCO.2011.35.6345"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Takahashi T, Sonobe M, Kobayashi M, et al. Clinicopathologic features of non-small-cell lung cancer with <i>EML<sub>4<\/sub>-ALK<\/i> fusion gene. Ann Surg Oncol 17: 889-897, 2010.","DOI":"10.1245\/s10434-009-0808-7"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368: 2385-2394, 2013.","DOI":"10.1056\/NEJMoa1214886"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380-2388, 2010.","DOI":"10.1056\/NEJMoa0909530"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371: 2167-2177, 2014.","DOI":"10.1056\/NEJMoa1408440"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Yamazoe M, Saijo H, Ishikawa T, Kobayashi T, Takahashi R. A case of crizotinib-induced esophagitis in a patient with <i>EML4-ALK<\/i>-positive lung adenocarcinoma. Haigan (Jpn J Lung Cancer) 53: 840-845, 2013 (in Japanese, Abstract in English).","DOI":"10.2482\/haigan.53.840"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Park J, Yoshida K, Kondo C, et al. Crizotinib-induced esophageal ulceration: a novel adverse event of crizotinib. Lung Cancer 81: 495-496, 2013.","DOI":"10.1016\/j.lungcan.2013.06.017"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Srivastava N, VanderLaan PA, Kelly CP, Costa DB. Esophagitis: a novel adverse event of crizotinib in a patient with ALK-positive non-small-cell lung cancer. J Thorac Oncol 8: e23-e24, 2013.","DOI":"10.1097\/JTO.0b013e31827e2451"},{"key":"11","unstructured":"11. Takakuwa O, Oguri T, Yokoyama M, et al. Esophagitis resulting from treatment with crizotinib for anaplastic lymphoma kinase rearrangement-positive lung adenocarcinoma: a case report. Mol Clin Oncol 2: 121-123, 2014."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Abdel Jalil A, Craig J, Bajaj R, Spurling T. Sever ulcerative esophagitis induced by crizotinib therapy. ACG Case Rep J 1: 82-84, 2014.","DOI":"10.14309\/crj.2014.8"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Hirai N, Sasaki T, Yamamoto Y, Ohsaki Y. Crizotinib-induced esophagitis developing during the course of treatment for adenocarcinoma of the lungs associated with the EML4\/ALK fusion gene. Haigan (Jpn J Lung Cancer) 54: 68-72, 2014 (in Japanese, Abstract in English).","DOI":"10.2482\/haigan.54.68"},{"key":"14","unstructured":"14. Pfizer: Crizotinib adverse events reported from clinical trials (PROFILE 1001 study and PROFILE 1005 study) [Intertet]. [cited 2014 Oct. 8]. Available from: https:\/\/pfizerpro.jp\/download.php?key=Cad1UdxtexCWBqUNzxhlMg=="},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Nosaka S, Yamaguchi S, Nagasawa T, Tahara M. Pharmacology profile of crizotinib (Xalkori<sup>&reg;<\/sup>Capsules) and clinical findings on this drug. Nippon Yakurigaku Zasshi (Folia Pharmacol Jpn) 141: 106-113, 2013 (in Japanese).","DOI":"10.1254\/fpj.141.106"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Satoh H, Inoue A, Kobayashi K, et al. Low-dose gefitinib treatment for patients with advanced non-small cell lung cancer harboring sensitive epidermal growth factor receptor mutations. J Thorac Oncol 6: 1413-1417, 2011.","DOI":"10.1097\/JTO.0b013e31821d43a8"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Fujita T, Teramoto K, Ozaki Y, et al. Retrospective study of alternate-day administration of gefitinib. Haigan (Jpn J Lung Cancer) 47: 9-12, 2007 (in Japanese, Abstract in English).","DOI":"10.2482\/haigan.47.9"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/54\/24\/54_54.4996\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T09:41:54Z","timestamp":1567417314000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/54\/24\/54_54.4996\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":17,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.54.4996","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}